Suchergebnisse - "Santini, Daniele"

PubPharm (914)

1

Clinical application of bladder MRI and the Vesical Imaging-Reporting and Data System

enthalten in: Nature reviews. Urology | 2024

von Panebianco, V. | Briganti, A. | Boellaard, T. | +21

2

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy : the ARON-2 study

enthalten in: Cancer immunology, immunotherapy : CII | 2024

von Massari, F. | Santoni, M. | Takeshita, H. | +94

3

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

enthalten in: Cancer immunology immunotherapy | 2024

von Massari, F. | Santoni, M. | Takeshita, H. | +94

4

Correction : Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

enthalten in: BMC cancer | 2024

von Cirillo, A. | Marinelli, D. | Romeo, U. | +14

ErratumFor: BMC Cancer. 2024 Apr 8;24(1):430. - PMID 38589857

5

Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

enthalten in: BMC cancer | 2024

von Cirillo, A. | Marinelli, D. | Romeo, U. | +14

6

Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib : A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)

enthalten in: Clinical genitourinary cancer | 2024

von Damassi, A. | Cremante, M. | Signori, A. | +20

7

Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors : results from a single-center cohort

enthalten in: Clinical and experimental medicine | 2024

von Ceccarelli, F. | Natalucci, F. | Picciariello, L. | +10

8

Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort

enthalten in: Clinical and experimental medicine | 2024

von Ceccarelli, F. | Natalucci, F. | Picciariello, L. | +10

9

Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma : a retrospective analysis

enthalten in: BMC cancer | 2024

von Cirillo, A. | Marinelli, D. | Romeo, U. | +14

ErratumIn: BMC Cancer. 2024 Apr 17;24(1):487. - PMID 38632499

10

Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

enthalten in: BMC cancer | 2024

von Cirillo, A. | Marinelli, D. | Romeo, U. | +14

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[92]